drug therapy

08/25/2014 - 19:00

Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas – the primary form of a deadly brain cancer – are resistant to drug therapy. The answer lies not in the DNA sequence of the tumor, but in its epigenetic signature. These findings have been published online as a priority report in the journal Oncotarget.


11/18/2013 - 13:44

A team of UIC researchers in medicine, engineering and pharmacy will study whether a therapy now used to treat drug overdoses may protect against chemical attack. The researchers are investigating a high-fat liquid, called a lipid emulsion, already approved as a nutritional supplement and used off-label to treat overdoses of anesthetics, beta blockers, calcium-channel blockers and certain antidepressants.


03/11/2013 - 12:24

People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center. The findings, part of the largest-ever MS trial sponsored by the National Institutes of Health, are published in the March 11 issue of Annals of Neurology.


11/05/2012 - 10:57

A drug therapy shows promise for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease (ADPKD), Mayo Clinic researchers say. The medication, tolvaptan, slowed the pace of kidney cyst growth over the three years of the study. The phase three clinical trial results were being presented today at the American Society of Nephrology annual meeting and published online in the New England Journal of Medicine.

08/07/2012 - 13:43

In order to treat acute megakaryoblastic leukemia (AMKL) in patients who do not respond to current therapies, researchers need a protein target at which to take aim. A new effort at the Broad Institute draws on the strengths of a large number of the Broad’s resources and platforms to identify such targets and narrow in on suitable drugs to pursue them. The study of AMKL has been one of the first projects to which this highly integrated approach has been applied, and findings point to the potential of a drug candidate currently under clinical investigation for the treatment of other forms of cancer.

02/17/2011 - 00:00

A readily available, inexpensive drug therapy showed a significant benefit in treating premature infants with the worst and historically most difficult-to-treat cases of retinopathy of prematurity.